Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

An ambulatory patient in her late sixties presents to the clinic to discuss her bone health after recent screening tests. Her dual-energy x-ray absorptiometry (DEXA) demonstrates a lumbar spine T-score of −2.8-2.8 and a femoral neck T-score of −2.4-2.4. She has a history of hypertension but no prior fragility fractures. The physician and patient agree to initiate weekly oral alendronate. Arrange the following interventions in the most appropriate chronological order to safely initiate, monitor, and manage this patient's therapeutic course.

  1. 1Verify adequate serum calcium and 25-hydroxyvitamin D levels
  2. 2Assess for medication adherence and upper gastrointestinal tolerability
  3. 3Obtain a follow-up dual-energy x-ray absorptiometry (DEXA) scan
  4. 4Evaluate clinical fracture risk to consider a therapeutic drug holiday

Answer

The correct chronological sequence is: Verify baseline calcium/vitamin D, assess early adherence and tolerability, perform a follow-up DEXA scan at 1-2 years, and finally evaluate for a drug holiday at 3-5 years.
The correct sequence mirrors the natural timeline of patient management: safety screening immediately prior to initiation, early clinical monitoring for acute toxicity and adherence, mid-term evaluation of therapeutic efficacy via imaging, and long-term evaluation for cumulative risks necessitating therapy de-escalation.

Step-by-Step Solution

1
Determine the prerequisites for initiation.
Serum calcium and vitamin D levels must be checked.
Bisphosphonates inhibit bone resorption, which can precipitate severe hypocalcemia if the patient lacks adequate calcium and vitamin D stores at baseline.
2
Identify early monitoring requirements.
Clinical follow-up for adherence and gastrointestinal side effects is prioritized next.
Oral nitrogen-containing bisphosphonates carry a high risk of erosive esophagitis and require strict administration protocols (taking with a full glass of water, remaining upright for 30 minutes). Early verification of adherence prevents acute harm.
3
Determine the interval for assessing intermediate drug efficacy.
A repeat DEXA scan is scheduled.
It takes at least 1 to 2 years for significant, measurable changes in bone mineral density to manifest on a DEXA scan. Earlier scanning does not provide clinically actionable data.
4
Determine the protocol for long-term treatment evaluation.
Assessment for a drug holiday is considered.
Because bisphosphonates accumulate in the bone matrix and have a very long half-life, a drug holiday is considered after 3 to 5 years of therapy to reduce the risk of long-term complications like atypical femur fractures.

Key Concept

The chronological protocol for monitoring and evaluating bisphosphonate therapy in patients with osteoporosis.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic